Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

ONCOLOGY

Volumn 11, Issue 9 SUPPL. 10, 1997, Pages 22-25

  Meropol, Neal J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLINIC ACID; UFT;

ADULT; AGED; BIOAVAILABILITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; TEGAFUR; URACIL;

EID: 0030829235     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Meropol NJ, Rustum YM, Petrelli NJ, et al: A phase I and pharmacokinetic study of oral uracil, Ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37:581-586, 1996.
2. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994,
3. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993.